For instance, inhibiting METTL1 has been demonstrated to improve responses to ICB therapy in preclinical models of PCa, and low expression of METTL1 is associated with favorable outcomes from ICB therapy [128]. Here, METTL1 is linked to posterior cortical atrophy.